ライフサイエンスコーパス: corticosteroid

1 or viral coinfections and immunosuppression (corticosteroids).

2 ents were treated with local infiltration of corticosteroid.

3 act development among eyes receiving topical corticosteroids.

4 IL-10) generally impaired by frequently used corticosteroids.

5 usion of food triggers and swallowed topical corticosteroids.

6 that are treated with high doses of inhaled corticosteroids.

7 n of offending drug and short course of oral corticosteroids.

8 ywords for oral corticosteroids and systemic corticosteroids.

9 use of lopinavir-ritonavir, interferons, and corticosteroids.

10 sk while limiting calcineurin inhibitors and corticosteroids.

11 andard-dose CNIs, mycophenolate mofetil, and corticosteroids.

12 ndard-exposure TAC (MMF + sTAC; n = 54) with corticosteroids.

13 ttenuated with concomitant use of statins or corticosteroids.

14 ed with attention paid to the use of topical corticosteroids.

15 body weight include progesterone analogs and corticosteroids.

16 sed optic canal decompression and the use of corticosteroids.

17 d were successfully treated with intravenous corticosteroids.

18 arding remission, and (4) no use of systemic corticosteroids.

19 p inhibitors, elimination diets, and topical corticosteroids.

20 cause the stunting of growth seen with these corticosteroids.

21 nation of intranasal H(1)-antihistamines and corticosteroids.

22 progesterone analogs and short-term (weeks) corticosteroids.

23 rential trabeculotomy or using postoperative corticosteroids.

24 JIA)-associated uveitis treated with topical corticosteroids.

25 common, used in 31%, followed by iNO (13%), corticosteroids (10%), prone positioning (10%), HFOV (9%

26 ampreys produces two predominant circulating corticosteroids, 11-deoxycortisol (S) and 11-deoxycortic

27 orbital disease with inadequate response to corticosteroids (44.4%) or a high suspicion of malignanc

28 ed intravenous immune globulin (IVIG) (71%), corticosteroids (61%), and anakinra (18%).

29 ts were more commonly treated with long-term corticosteroids (73%), whereas German patients were more

30 0% IE vs. 13% WNE, P < .001) and use inhaled corticosteroids (77% FE vs. 15% IE vs. 18% WNE, P < .001

31 Thirty-four were treated with corticosteroids (83%), 11 with an immunosuppressant trea

32 sporine, both with mycophenolate mofetil and corticosteroids; 95/115 randomized patients were followe

33 oved from the study and treated with topical corticosteroids according to best medical judgment.

34 s used in eight studies as a measure of oral corticosteroid adherence, and fractional exhaled nitric

35 itric oxide (FeNO) in 17 studies for inhaled corticosteroid adherence.

36 patients continue to be prescribed systemic corticosteroids after CSC diagnosis.

37 Patients who used corticosteroids after surgery were more likely to experi

38 In this mouse model, treatment with corticosteroid allows for initial proliferation and sust

39 scale) after a 1-hour treatment with an oral corticosteroid and 3 inhaled albuterol and ipratropium t

40 caused by type 2 cytokines is responsive to corticosteroid and biologic therapies, many severe asthm

41 Corticosteroid and high-dose intravenous immunoglobulin

42 uding 208 (44%) prescribed high-dose inhaled corticosteroids and 122 (31%) with severe asthma.

43 active NIPPU after failure of treatment with corticosteroids and a second-line immunosuppression drug

44 logic agents after failure of treatment with corticosteroids and a second-line immunosuppression drug

45 The patient refused oral corticosteroids and any intravitreal injection therapies

46 eviously unsuspected roles for oncostatin M, corticosteroids and ephrins in mediating cellular respon

47 g function, require more courses of systemic corticosteroids and have greater limitation of activitie

48 by conventional therapy only, consisting of corticosteroids and immunosuppressants.

49 Corticosteroids and immunosuppressive drugs were largely

50 (6) optimal dosing regimens for intravenous corticosteroids and infliximab in these patients, and (7

51 Dispensed inhaled corticosteroids and inhaled beta-agonists were associate

52 airway obstruction despite massive doses of corticosteroids and maximal pharmacologically induced br

53 -term use of anti-inflammatory drugs such as corticosteroids and nonsteroidal anti-inflammatory drugs

54 he age of fourteen, and the addition of oral corticosteroids and omalizumab to regular inhaled cortic

55 Management is primarily based on corticosteroids and other immunomodulatory agents, which

56 ry to traditional antirejection therapy with corticosteroids and polyclonal antilymphocyte globulin.

57 verity, exacerbations, and responsiveness to corticosteroids and potential for response to anti-Type

58 ment options were confined to application of corticosteroids and symptomatic management, without prov

59 arch terms for asthma with keywords for oral corticosteroids and systemic corticosteroids.

60 a aged 6 to 16 years taking low-dose inhaled corticosteroids and with serum 25-hydroxyvitamin D level

61 te GVHD respond to first-line treatment with corticosteroids and, for several decades, there was no o

62 ts with fast-acting immunosuppressive drugs (corticosteroids and/or cyclosporine) to reduce inflammat

63 RSwNP with inadequate response to intranasal corticosteroids, and it was well tolerated.

64 clude discontinuation of the specific agent, corticosteroids, and other immune suppressing agents for

65 The combination of ascorbic acid, corticosteroids, and thiamine has been identified as a p

66 multicenter clinical trial of ascorbic acid, corticosteroids, and thiamine vs placebo for adult patie

67 tic shock, the combination of ascorbic acid, corticosteroids, and thiamine, compared with placebo, di

68 Of these, 10 were treated with corticosteroids, and three of these patients also receiv

69 Race, gender, and corticosteroids apparently did not influence RNA positiv

70 Corticosteroids are a possible therapeutic option.

71 vir has not been shown to have efficacy, and corticosteroids are currently not recommended.

72 Swallowed topical-acting corticosteroids are effective in bringing active EoE int

73 However, inhaled or systemic corticosteroids are ineffective treatments in many patie

74 Depot parenteral corticosteroids are not recommended for treatment of AR

75 effects of allergic immune dysregulation and corticosteroids are poorly understood.

76 rine and antihistamines followed by systemic corticosteroids are the mainstays of therapy for acute e

77 o help ameliorate the inflammatory response, corticosteroids are used as an adjuvant to standard anti

78 When corticosteroids are used for a long time in patients wit

79 d effects of asthma-controlling medications (corticosteroids) as factors that predispose patients wit

80 Corticosteroid-associated AEs of elevated intraocular pr

81 effects of vamorolone on motor outcomes and corticosteroid-associated safety concerns.

82 egy to avoid both calcineurin inhibitors and corticosteroids at this time.

83 pt-based strategies employing tacrolimus and corticosteroid avoidance.

84 are not fully understood, and treatment with corticosteroids, biologics, and surgical intervention ar

85 and transplant-related covariates and use of corticosteroids, bisphosphonates, vitamin D and calcium

86 uch as chronic lymphopenia and/or history of corticosteroid boluses could be useful to avoid life-thr

87 osuppressive drugs and the administration of corticosteroid boluses used in acute rejection.

88 Oral corticosteroid bursts are frequently prescribed in the g

89 here appropriate, we estimated the effect of corticosteroids by random-effects meta-analyses using th

90 sivir, lopinavir-ritonavir, interferon beta, corticosteroids, chloroquine and hydroxychloroquine, and

91 inflammatory markers 1 week after receiving corticosteroids (CS) (p<0.003).

92 Although corticosteroids dampen the dysregulated immune system an

93 2009 compared to 51.4% in 2018) and topical corticosteroids decreased (57.3%-52.0%).

94 at high risk for colectomy, hospitalization, corticosteroid dependence, and serious infections.

95 lucocorticoid receptor (GR) by the synthetic corticosteroid dexamethasone (DEX) stimulates bovine her

96 e natural polyphenol curcumin (CURC) and the corticosteroid dexamethasone (DEX).

97 The synthetic corticosteroid dexamethasone consistently induces BoHV-1

98 ncy is consistently induced by the synthetic corticosteroid dexamethasone.

99 The ongoing use of inhaled corticosteroids did not increase the risk of hospitaliza

100 3 Ds: drugs (particularly swallowed topical corticosteroids), dietary restriction, and endoscopic di

101 The corticosteroid domain randomized participants to a fixed

102 mized to open-label interventions within the corticosteroid domain.

103 plications increase with the cumulative oral corticosteroid dosage.

104 alysis was used to assess the association of corticosteroid dose and mortality.

105 nib and corticosteroids had a 50% or greater corticosteroid dose reduction from baseline.

106 (2) agonist therapy to a maintenance inhaled corticosteroid dose that causes the same magnitude of sy

107 We analyzed relapse and temporal daily corticosteroid dose with and without co-administration o

108 ion, but the evidence relates mainly to high corticosteroid doses and is of low quality with potentia

109 a fall in FeNO following supervised inhaled corticosteroid dosing could indicate previous poor adher

110 ine (AZA), baricitinib, ciclosporin A (CSA), corticosteroids, dupilumab, interferon-gamma, intravenou

111 lation or >=2 courses of blinded rescue oral corticosteroids) during the study; in addition, patients

112 k 24 because of an increased placebo/topical corticosteroid effect (36.8% vs 21.1%, P = .06).

113 Systemic exposure to high-dose corticosteroids effectively combats acute rejection afte

114 Greater oral/systemic corticosteroid exposure was also associated with increas

115 t comparison of its use with observation and corticosteroids failed to confirm the usefulness of this

116 x stromal keratitis who had not received any corticosteroids for at least 10 days before study enroll

117 right eye and the recent use of intravenous corticosteroids for bronchitis.

118 ith Septic Shock and Activated Protein C and Corticosteroids for Human Septic Shock trials.

119 ith Septic Shock and Activated Protein C and Corticosteroids for Human Septic Shock trials.

120 Shock) and $30,911 (Activated Protein C and Corticosteroids for Human Septic Shock) per patient.

121 Per Activated Protein C and Corticosteroids for Human Septic Shock, adjunctive hydro

122 sex, CMV mismatch, interleukin-2 inhibitors, corticosteroids for rejection, and plasmapheresis were n

123 pic mucosal healing, clinical remission, and corticosteroid-free remission at week 44 (all P < .05) i

124 y higher percentage of patients establishing corticosteroid-free state for the first time throughout

125 ith placebo in out- and inpatients, systemic corticosteroids given for 9 to 56 days were associated w

126 d at a significantly lower rate in the early corticosteroid group (34.9% vs 54.3%, P = .005).

127 ength of stay was also observed in the early corticosteroid group (5 vs 8 days, P < .001).

128 Outcomes of standard of care (SOC) and early corticosteroid groups were evaluated, with a primary com

129 cts, 81 (38%) and 132 (62%) in SOC and early corticosteroid groups, respectively.

130 8%) of 43 patients receiving ruxolitinib and corticosteroids had a 50% or greater corticosteroid dose

131 Immunosuppression devoid of corticosteroids has been investigated to avoid long-term

132 Long-term use of oral corticosteroids has known adverse effects, but the risk

133 Inhaled corticosteroids have been the foundation for asthma trea

134 stimulatory blockade strategies that include corticosteroids have recently shown promise, despite the

135 gnaling System (RAAS) involve binding of the corticosteroid hormone, aldosterone to its mineralocorti

136 Corticosteroids, however, can have a wide range of effec

137 ICANS is currently managed with corticosteroids; however, the optimal dose and duration

138 Intra-articular corticosteroid (IACS) injections are often used for pain

139 ns.Objectives: To understand whether inhaled corticosteroid (ICS) withdrawal affected IMPACT results,

140 lines were updated to recommend that inhaled corticosteroid (ICS)/long-acting beta (2)-adrenoceptor a

141 The combination drug of inhaled corticosteroid (ICS)/long-acting beta2 agonist is being

142 ms underlying hyperinflation and how inhaled corticosteroids (ICS) affect this important aspect of CO

143 Inhaled corticosteroids (ICS) are a mainstay of treatment in eos

144 Rationale: Inhaled corticosteroids (ICS) are key treatments for controlling

145 uctive pulmonary disease (COPD) with inhaled corticosteroids (ICS) is controversial, because it can r

146 In patients on high-dose inhaled corticosteroids (ICS) with type 2-high asthma (subgroups

147 n for the use of triple therapy with inhaled corticosteroids (ICS)/LABA/LAMA over dual therapy with L

148 Inhaled corticosteroids (ICSs) are widely used in COPD, but the

149 e anti-inflammatory maintenance with inhaled corticosteroids (ICSs) has been reserved for patients wi

150 r-level medication: medium/high-dose inhaled corticosteroids (ICSs) or ICSs + add-on medication (long

151 mized to observation in the Standard Care vs Corticosteroid in Retinal Vein Occlusion Study.

152 ich could be suppressed by the addition of a corticosteroid in vitro.

153 imab, tacrolimus, mycophenolate mofetil, and corticosteroids in 80% of patients, whereas 20% received

154 eitis, and concomitant use of other forms of corticosteroids in a time-updated fashion, treatment wit

155 They consider the indications for inhaled corticosteroids in COPD, when inhaled corticosteroids sh

156 Proper use corticosteroids in general type patients did not delay v

157 reveal an association, but reported doses of corticosteroids in included studies were high (mostly >

158 Although our results using topical corticosteroids in mice are highly promising for recover

159 rescribing of potent and very potent topical corticosteroids in non-white ethnicities and people of l

160 endation against the use of maintenance oral corticosteroids in patients with COPD and a history of s

161 To analyze the application of corticosteroids in patients with severe pneumonia.

162 eview updates the current evidence regarding corticosteroids in the treatment of influenza and examin

163 We examined the role of the endogenous corticosteroids in vivo and ex vivo in sea lamprey (Petr

164 c interventions for inpatients refractory to corticosteroids, in reducing risk of colectomy, (6) opti

165 zation, requiring a short course of systemic corticosteroids; in 4 cases, this occurred within 72 hou

166 Intranasal corticosteroids (INCS) remain the preferred monotherapy

167 atients with CRSwNP refractory to intranasal corticosteroids (INCS) significantly improved endoscopic

168 mbined plasmapheresis, HDIVig, and high-dose corticosteroids induced the complete remission of neurol

169 costeroids and omalizumab to regular inhaled corticosteroid inhalation failed to relieve symptoms.

170 or PARDS: continuous neuromuscular blockade, corticosteroids, inhaled nitric oxide (iNO), prone posit

171 Corticosteroids inhibited Interleukin-6(IL-6) production

172 costeroid prescription or code for an ocular corticosteroid injection within 120 days of the uveitis

173 d to < 4 mm when assessed after six weeks of corticosteroid injection.

174 bronchodilators, whereas the role of inhaled corticosteroids is less clear.

175 Treatment with corticosteroids is recommended for Duchenne muscular dys

176 We predict that increased corticosteroid levels activate the glucocorticoid recept

177 f there is a progressive increase in inhaled corticosteroid/long-acting beta(2) agonist therapy to a

178 Application of lower dose corticosteroids (<= 2 mg/kg day) could inhibit IL-6 prod

179 nsight as to how adding a LABA to an inhaled corticosteroid may improve clinical outcomes in asthma.

180 Corticosteroids may be beneficial in sepsis, but uncerta

181 ostoperative NSAIDs alone, which may suggest corticosteroid-mediated outflow obstruction distal to th

182 anasal Sinuses (TEMPS) is developed with the corticosteroid mometasone furoate.

183 ents in some motor outcomes as compared with corticosteroid-naive individuals over an 18-month treatm

184 tly different between vamorolone-treated and corticosteroid-naive participants (p = 0.088; least squa

185 ficant improvement compared to group-matched corticosteroid-naive participants for run/walk 10 meters

186 in the CINRG Duchenne Natural History Study (corticosteroid-naive, n = 19; corticosteroid-treated, n

187 Oral corticosteroid (OCS) treatment for severe asthma is asso

188 Despite reports of visual improvement with corticosteroids, optic canal decompression, and medical

189 al or ocular H(1)-antihistamines, intranasal corticosteroids or a fixed combination of intranasal H(1

190 ssessment of clinical status, and the use of corticosteroids or antiangiogenics.

191 findings suggest that children using inhaled corticosteroids or inhaled beta-agonists might be at inc

192 utic domains, for example, antiviral agents, corticosteroids, or immunoglobulin.

193 aft rejection, CMV infection, higher dose of corticosteroids, or prolonged neutropenia.

194 The use of corticosteroids (P: 0.007) and history of chronic respir

195 s randomized to implant or systemic therapy (corticosteroid plus immunosuppression in >90%) were foll

196 d contrast agents (GBCAs) that occur despite corticosteroid premedication (breakthrough reactions) ar

197 hen compared with use of the same agent with corticosteroid premedication (P = .10).

198 pectively) from the observed rate when using corticosteroid premedication and the same GBCA (36%; 95%

199 , 95%; four of five administrations) without corticosteroid premedication, which did not differ (P =

200 For the alternative outcome definition, a corticosteroid prescription or code for an ocular cortic

201 We compared systemic corticosteroid prescriptions before and after CSC diagno

202 Comedications containing corticosteroids, quetiapine, or antithrombotic agents we

203 levels in the blood, adherence rates to oral corticosteroids ranged from 47% to 92%, although the per

204 e, lampreys express only a single, ancestral corticosteroid receptor (CR).

205 Antibiotics and systemic corticosteroids reduce treatment failure in adults with

206 Although mechanisms for corticosteroid refractory asthma are likely to be numero

207 a new model for treating some patients with corticosteroid refractory asthma.

208 b was recently approved for the treatment of corticosteroid-refractory acute GVHD in adult and pediat

209 timal second-line treatment of patients with corticosteroid-refractory acute GVHD.

210 the ERBB receptor and ligand family to drive corticosteroid-refractory inflammation should enhance th

211 e asthma: on the one hand driving pathologic corticosteroid-refractory mixed granulocytic inflammatio

212 The topical corticosteroid regimen used in this study was significan

213 ey and that receptor-mediated discriminative corticosteroid regulation of hydromineral balance is an

214 ed improvements were similar in magnitude to corticosteroid-related improvements.

215 s of psoriasis, topical therapies, primarily corticosteroids, remain the mainstay of treatment to red

216 us radiotherapy, no neurological symptoms or corticosteroid requirement, and Eastern Cooperative Onco

217 can drive both corticosteroid-sensitive and corticosteroid-resistant responses.

218 tification of sputum eosinophilia indicating corticosteroid responsiveness in subjects with severe as

219 onse was explored in participants undergoing corticosteroid responsiveness testing with intramuscular

220 der how to reconcile the negative effects of corticosteroids revealed by Liu and Zhang et al. with th

221 pro-allergic cytokine, IL-13, can drive both corticosteroid-sensitive and corticosteroid-resistant re

222 nhaled corticosteroids in COPD, when inhaled corticosteroids should be withdrawn, and what other trea

223 ther and how osmoregulation is controlled by corticosteroid signaling in the phylogenetically basal v

224 starting oxygenation index of each therapy; corticosteroids started at the lowest oxygenation index

225 Swallowed topical corticosteroids (STC) belong to the therapeutic cornerst

226 eatment consisted of various combinations of corticosteroids (systemic, intravitreal, and topical), a

227 and PIIRS were treated with adjunctive pulse corticosteroid taper therapy (PCT) consisting of intrave

228 challenge and risk of relapse of irAE-N, and corticosteroid taper, which are not specifically address

229 Administration of corticosteroids that permitted higher levels of bacteria

230 o percent had red flagged PDDIs (mostly with corticosteroids), the same as in the 2008 survey.

231 nse prompted us to examine the role of early corticosteroid therapy in patients with moderate to seve

232 Compared with placebo, corticosteroid therapy reduced the risk of persistent or

233 l II study and 6 level III studies) explored corticosteroid therapy that did not have uniformly bette

234 Systemic corticosteroid therapy was associated with improved visu

235 Eyes treated with systemic corticosteroid therapy were identified for further analy

236 articularly following exposure cessation and corticosteroid therapy, but the time course to improveme

237 60 eyes in 40 patients who received topical corticosteroid therapy, there was a dose-dependent incre

238 When treated with corticosteroids, this resolved or regressed at follow-up

239 We further determined the impact of topical corticosteroids to reactivate Borrelia locally in the sk

240 uspended and intensive treatment with potent corticosteroids (topical, subtenon, intravitreal, or sys

241 Corticosteroid-treated participants showed stunting of g

242 History Study (corticosteroid-naive, n = 19; corticosteroid-treated, n = 68) over a similar 18-month

243 However, chronic corticosteroid treatment causes significant morbidities.

244 Although the efficacy of corticosteroid treatment in controlling asthma is widely

245 benefit based on inputs from the Adjunctive Corticosteroid Treatment in Critically Ill Patients with

246 at a dose of 200 mg/d for 7 d for Adjunctive Corticosteroid Treatment in Critically Ill Patients with

247 omes were aggregate data from the Adjunctive Corticosteroid Treatment in Critically Ill Patients with

248 Per Adjunctive Corticosteroid Treatment in Critically Ill Patients with

249 ter monetized benefit of $10,658 (Adjunctive Corticosteroid Treatment in Critically Ill Patients with

250 t studies reporting corticosteroid versus no corticosteroid treatment in individuals with influenza.

251 Corticosteroid treatment in influenza is associated with

252 e of the JCI, Liu and Zhang et al. evaluated corticosteroid treatment in more than 400 patients with

253 Maternal antenatal corticosteroid treatment is standard care to accelerate

254 ction timing, bacteria/fungal infection, and corticosteroid treatment limit interpretation, we believ

255 cohort study, exposure to maternal antenatal corticosteroid treatment was significantly associated wi

256 nia are likely to benefit from moderate-dose corticosteroid treatment when administered relatively la

257 Of the 14 868 (2.22%; 46.1% female) corticosteroid treatment-exposed children, 6730 (45.27%)

258 Maternal antenatal corticosteroid treatment.

259 f both diagnostic codes and documentation of corticosteroid treatment.

260 lp inform decisions about maternal antenatal corticosteroid treatment.

261 al-acquired infection in people treated with corticosteroids (unadjusted odds ratio, 2.74; 95% CI, 1.

262 actor receptor (EGFR/ERBB1) as a mediator of corticosteroid-unresponsive inflammation and bronchial h

263 ic therapies, many severe asthmatics exhibit corticosteroid-unresponsive mixed granulocytic inflammat

264 ib orally, starting at 5 mg twice daily plus corticosteroids, until treatment failure, unacceptable t

265 a history of ocular surgery (62.5%), topical corticosteroid use (35.4%), and dry eye syndrome (37.5%)

266 are utilization (r = 0.48; P = .03) and oral corticosteroid use (r = 0.43; P = .05) at baseline.

267 es a comprehensive overview of oral/systemic corticosteroid use and associated adverse events for pat

268 o assess the associations between asthma and corticosteroid use and the risk of COVID-19-related hosp

269 Evidence regarding corticosteroid use for severe coronavirus disease 2019 (

270 the real-world extent and burden of systemic corticosteroid use in asthma.

271 nomic analyses, and surveys on oral/systemic corticosteroid use in children (>5 yr old), adolescents

272 A prospective, randomized trial of systemic corticosteroid use in endophthalmitis may be warranted.

273 We report that oral/systemic corticosteroid use is prevalent in asthma management, an

274 Systemic corticosteroid use to manage uncontrolled asthma and its

275 Long-term oral/systemic corticosteroid use was, in general, less frequent than s

276 ease severity, nasal polyposis, and systemic corticosteroid use were also associated with frequent AE

277 g-term and repeated short-term oral/systemic corticosteroid use were associated with an increased ris

278 Poor ocular surface, topical corticosteroid use, previous ocular surgery, and/or a hi

279 zation associated with asthma and/or inhaled corticosteroid use.

280 severity, health care utilization, and oral corticosteroid use.

281 (asthma, eczema, and allergic rhinitis) and corticosteroid use.

282 , and observational cohort studies reporting corticosteroid versus no corticosteroid treatment in ind

283 tively low myelotoxicity profiles, including corticosteroids, vincristine, L-asparaginase, methotrexa

284 nstay of treatment, and they include topical corticosteroids, vitamin D analogues, calcineurin inhibi

285 on, treatment with <3 drops daily of topical corticosteroid was associated with an 87% lower risk of

286 of participants in whom the dose of inhaled corticosteroid was reduced halfway through the trial, an

287 ortion of participants whose dose of inhaled corticosteroid was reduced, or the cumulative fluticason

288 Use of topical corticosteroids was associated with cataract formation i

289 led corticosteroids with or without systemic corticosteroids was not associated with COVID-19-related

290 Corticosteroids were associated with a higher rate of AR

291 Overall, oral/systemic corticosteroids were commonly used for asthma management

292 Inhaled corticosteroids were measured directly in the blood in o

293 Eyes that received postoperative corticosteroids were more likely to experience an IOP sp

294 Additionally, topical corticosteroids were prescribed in 18 eyes and tapered d

295 RSwNP with inadequate response to intranasal corticosteroids were randomized (1:1) to omalizumab or p

296 High-dose corticosteroids with IMT within 3 months resulted in imp

297 Similarly, the use of inhaled corticosteroids with or without systemic corticosteroids

298 eptor antagonist tocilizumab with or without corticosteroids, with questions remaining regarding the

299 xposure tacrolimus (EVR + rTAC; n = 52) with corticosteroid withdrawal at 6-month posttransplant or c

300 ncing rejection under belatacept-based early corticosteroid withdrawal following T-cell-depleting ind